30 Alere Cholestech LDX
®
System User Manual
Risk Assessment
Coronary Heart Disease (CHD)
Risk Assessment Program
The Alere Cholestech LDX
®
CHD Risk Assessment Program is
based on data from the Third Report of the National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation,
and Treatment of High Blood Cholesterol in Adults.* The
relationship between these risk factors and CHD is derived from the
Framingham Study.
The Framingham Study documents and tracks the effects of
variables involved in the development of CHD. The age range for
the study is 20–79 years, and includes both men and women.
The risk assessment program may be used with any test
cassette that provides results for both total cholesterol and
HDL cholesterol. This program calculates the percentage risk of
developing coronary heart disease (CHD) over 10 years based on
test results and the following risk factors:
• Sex (male, female)
• Smoking (yes, no)
• Age (20–79)
• SBP (systolic blood pressure)
• SBP has been treated or not treated
• The risk calculation is valid for persons 20–79 years of
age who are currently free of CHD.
Although the effects of family medical history, obesity and
exercise may be relevant, they were not included as separate
risk factors in the risk assessment developed by the Framingham
Study.
*Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive
summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA
2001; 285:2486-97.
To Next Page
Loading...
Need help?
General
